DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Baeten D, Ostergaard M, Wei JC. et al.
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Ann Rheum Dis 2018;
77: 1295-1302 doi: 10.1136/annrheumdis-2018-213328
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.